Literature DB >> 8112357

Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS.

J Saba1, P Morlat, F Raffi, V Hazebroucq, V Joly, C Leport, J L Vildé.   

Abstract

A prospective study was conducted to evaluate azithromycin in combination with pyrimethamine for treatment of acute Toxoplasma encephalitis in patients with AIDS. Of the 14 patients given 75 mg pyrimethamine and 500 mg azithromycin daily for four weeks, eight were evaluable for clinical response. Five responded favorably, one had an intermediate response and two an unfavorable response. Of the nine patients evaluable for radiological response, six responded favorably, and three had an intermediate response. Eleven adverse events occurred in nine patients: rash (n = 5), abnormal liver function (n = 2), vomiting (n = 3) and hypoacousia (n = 1). This pilot study suggests that the combination of pyrimethamine and azithromycin may be further investigated and that the optimal dosage of azithromycin has yet to be determined.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8112357     DOI: 10.1007/bf02000407

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  Clindamycin for toxoplasma encephalitis in AIDS.

Authors:  J S Remington; J L Vildé
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

2.  Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii.

Authors:  J Huskinson-Mark; F G Araujo; J S Remington
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

3.  Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group.

Authors:  B Dannemann; J A McCutchan; D Israelski; D Antoniskis; C Leport; B Luft; J Nussbaum; N Clumeck; P Morlat; J Chiu
Journal:  Ann Intern Med       Date:  1992-01-01       Impact factor: 25.391

4.  Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy.

Authors:  C Leport; F Raffi; S Matheron; C Katlama; B Regnier; A G Saimot; C Marche; C Vedrenne; J L Vilde
Journal:  Am J Med       Date:  1988-01       Impact factor: 4.965

Review 5.  Toxoplasmic encephalitis in AIDS.

Authors:  B J Luft; J S Remington
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079

6.  Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis.

Authors:  J C Mertens; P W van Barneveld; H R Asin; E Ligtvoet; M R Visser; T Branger; A I Hoepelman
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

7.  Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis.

Authors:  F Derouin; R Almadany; F Chau; B Rouveix; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

8.  Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia.

Authors:  D J Swanson; R J Sung; M J Fine; J J Orloff; S Y Chu; V L Yu
Journal:  Am J Med       Date:  1992-01       Impact factor: 4.965

9.  In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.

Authors:  H R Chang; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

10.  Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS.

Authors:  J Fernandez-Martin; C Leport; P Morlat; M C Meyohas; J P Chauvin; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

View more
  5 in total

1.  Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS.

Authors:  H Klinker; P Langmann; E Richter
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

Review 2.  Central nervous system infections in individuals with HIV-1 infection.

Authors:  Arunima Mamidi; Joseph A DeSimone; Roger J Pomerantz
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

Review 3.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

4.  Treatment of toxoplasmic encephalitis with the combination of clindamycin plus azithromycin in an HIV-infected patient: A case report.

Authors:  Keyhan Mohammadi; Hossein Khalili; Sirous Jafari; Shakila Yaribash
Journal:  Clin Case Rep       Date:  2021-03-24

Review 5.  Treatment of toxoplasmosis: Current options and future perspectives.

Authors:  Neda Konstantinovic; Hélène Guegan; Tijana Stäjner; Sorya Belaz; Florence Robert-Gangneux
Journal:  Food Waterborne Parasitol       Date:  2019-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.